ROIV Roivant Sciences
$34.21 -1.55%
US Stock · Health Care
RSI (14) · 30 / 70 bands
MACD (12, 26, 9)
Solid = close · dashed = 50-day MA · bars = volume. Toggle Bollinger / RSI / MACD. Hover to inspect. EOD data.
1D
-1.55%
YTD
+112.20%
P/E
—
P/B
4.38
ROE
-6.1%
Div yield
—
Beta
0.99
Market cap
$25.8B
RSI (14)
35
Next earnings
—
Previous session
close of Oct 8, 2026 · EOD, no live order bookOpen
$34.28
Close
$34.21
VWAP (n/a)
—
Day high
$34.56
Day low
$33.32
Volume
6.4M
VWAP = daily turnover ÷ volume — the volume-weighted average, the closest EOD read on where trading actually clustered. A true order book is live-only and needs a broker feed. Turnover/VWAP available for MOEX listings.
Latest headlines
IMVT, ROIV Stocks Slide As Argenx Sjögren’s Trial Failure Hits Drug Class
Yahoo Finance · Oct 8
Roivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 Months
Yahoo Finance · Sep 28
Roivant’s Lung Drug Clears Phase 2 Test: Is Another Major Pipeline Asset Emerging?
Yahoo Finance · Sep 24
Roivant’s Immunovant Stops IMVT-1402 Development in Cutaneous Lupus After Trial Miss
Yahoo Finance · Sep 23
Roivant (ROIV): $9 Billion Sales Potential Faces a Commercialization Test
Yahoo Finance · Sep 22
What Is Roivant Sciences (ROIV) Signaling With Its Positive PH ILD Trial Data?
Yahoo Finance · Sep 18
Headlines via Yahoo Finance · links open the source · not an endorsement.
Recent SEC filings
8-K Sep 18, 2026 View → 8-K Sep 8, 2026 View → 8-K Aug 28, 2026 View → 8-K Aug 27, 2026 View → 10-Q Aug 6, 2026 View →
Source: SEC EDGAR · opens the official filing.
Research & reports
External resources — availability and opinions are theirs, not ours.
This is reference data for your own analysis — not a recommendation to buy or sell ROIV. Try it in the Lab to size a position and see the risk.